drugset / Trial / NCT06892548
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).
Timeline
- Start
- 2025-05-02
- Primary completion
- 2028-09
- Completion
- 2032-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BNT324 | Other / unclassified | — | Intravenous |
| Subject | Pumitamig | Protein / enzyme biologic | — | Intravenous |